Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kidney study findings could boost the market for embolic protection devices

This article was originally published in Clinica

Executive Summary

In what could boost sales of coronary embolic protection devices, an independent study has found that such devices may also be used to successfully remove harmful emboli in blood vessels supplying the kidney during routine angioplasty and stenting. In current procedures, emboli - abnormal particles such as blood clots that clog-up the vessel - can become dislodged and cause further harm elsewhere. If the devices can gain worldwide approval for this new indication, their use could be expanded to a further 100,000 procedures a year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT052263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel